We also hypothesised that the ‘hit’ drugs may inhibit endogenous TBX2 and/or TBX3 in other TBX2/3‐driven cancers including rhabdomyosarcoma (RMS). This evidence concerns the gene TBX2 and rhabdomyosarcoma.